Drastic Reduction of Turnaround Time After Implementation of a Fully Automated Assay for RAS-BRAF Mutations in Colorectal Cancer: A Pilot Prospective Study in Real-life Conditions.

In conclusion, this pilot project shows that the Idylla™ platform for testing KRAS and NRAS/BRAF mutations allows an optimized turnaround time from test prescription to reception of results.
PMID: 32572821 [PubMed - as supplied by publisher]

Source: Pathology Oncology Research - June 21, 2020 Category: Pathology Authors: Rossat S, Perrier H, Lefevre M, Louvet C, Le Berre N, Chamois J, Dorel M, Vacque D, Guillaudeau A, Genet D, Maillet E, Triby S, Sabourin JC Tags: Pathol Oncol Res Source Type: research